Name: | Description: | Size: | Format: | |
---|---|---|---|---|
7.17 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Lipid-based Delivery Systems (LDS) has been the focus of potential strategies in drug delivery for
several years. A great deal of work has been invested on how to exploit their biocompatible and
biodegradable nature, in combination with their nanosize range in a profitable way in the field of
nanomedicines. A number of drugs loaded in LDS have been already tested in vivo successfully.
However, in vivo behaviour of nanosized materials differs from their bulk counterparts (and also
change drug properties), mainly depending on the particular LDS physicochemical characteristics.
These may have huge impact on the toxicity of the system, despite the physiological nature of the
lipid materials. This note on the regulatory concerns and toxicity assessment in LDS suggests that
current knowledge of public and scientific communities is lacking, requiring intensive research and
policy measures to provide a deep understanding on toxicological risks.
Description
Keywords
Lipid-Based Delivery Systems LDS Toxicity Cytotoxicity Genotoxicity Lipid Materials Nanoparticles